Blackstone drops $250M on a smarter way to manage a cystic fibrosis daily burden

For roughly 30,000 Americans with cystic fibrosis, managing exocrine pancreatic insufficiency means a daily math problem: how many enzyme pills can I fit before every meal, every snack, every day of my life. Some patients take up to 40 tablets a day of the standard pig-derived therapy. Blackstone Life Sciences thinks it has a better answer, and it just put $250 million behind the bet.

The private equity giant invested in Anagram Therapeutics on May 7, 2026, to push ANG003, an oral enzyme replacement therapy that would be the first non-porcine alternative to the existing standard of care. The current therapy works, but it is sourced from pig pancreas tissue, requires careful dosing and sometimes refrigeration, and leaves patients juggling dozens of pills daily. Anagram's approach uses a microbial source instead.

The investment is the largest single capital commitment Anagram has received and the first major deployment from Blackstone's record $6.3 billion life sciences fund, which closed in March 2026. It signals that Blackstone thinks a non-porcine, lower-burden oral alternative is both scientifically achievable and commercially viable at a scale that justifies a nine-figure check.

Anagram completed Phase 1 dosing for ANG003 in July 2024 and presented results at the North American Cystic Fibrosis Conference that same September. A peer-reviewed publication01529-2/fulltext) of the Phase 1 data appeared in the Journal of Cystic Fibrosis in July 2025. The Cystic Fibrosis Foundation previously committed up to $15.5 million in early-stage funding for the same program.

Whether ANG003 reaches patients depends on Phase 3 results and regulatory review, a process that can stretch years beyond a promising Phase 1. Anagram has not announced when it expects to begin a pivotal trial or file for approval. The field has seen oral enzyme programs stall before. But Blackstone's bet, large and programmatic, suggests the firm sees a credible path through development.

For CF patients and their families, the immediate stakes are practical. Standard pancreatic enzyme replacement therapy requires multiple pills before every meal and most snacks, on top of airway clearance treatments, inhaled medications, and nutritional supplements. Whether a new oral alternative meaningfully improves quality of life depends on whether it works, what it costs, and whether insurers cover it. Those questions remain open.